ABSCIENCES (EPA:AB) | Finanzwire

PRESS RELEASE

published on 09/23/2024 at 17:51, 1 year 7 months ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024, showing promising results in phase 2B/3 study AB07002

Phase 3 Study AB Science Masitinib ECTRIMS 2024 Progressive Multiple Sclerosis
BRIEF

published on 07/08/2024 at 08:01, 1 year 9 months ago

AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19

COVID-19 Clinical Trial Phase 2 Study AB Science Masitinib
PRESS RELEASE

published on 07/08/2024 at 07:56, 1 year 9 months ago

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment

COVID-19 Treatment Phase 2 Study AB Science Masitinib
BRIEF

published on 06/28/2024 at 12:36, 1 year 10 months ago

AB Science provides an update on the application for authorization of masitinib in ALS

ALS AB Science Masitinib EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 12:31, 1 year 10 months ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations

AB Science Masitinib CHMP ALS Treatment Conditional Marketing Authorization
BRIEF

published on 06/27/2024 at 10:20, 1 year 10 months ago

AB Science - Results of the Combined General Meeting of June 26, 2024

Shareholders Share Capital Resolutions General Assembly AB Science
BRIEF

published on 05/17/2024 at 18:03, 1 year 11 months ago

Correction of the Consolidated Accounts of AB Science for 2023

Financial Results Research And Development Consolidated Accounts AB Science Accounting Correction
BRIEF

published on 05/15/2024 at 20:21, 1 year 11 months ago

Reduction in operational losses and significant advances in clinical development for AB Science in 2023

Financial Results Clinical Development AB Science Masitinib Amyotrophic Lateral Sclerosis
PRESS RELEASE

published on 05/15/2024 at 20:16, 1 year 11 months ago

AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science presents financial information for the year 2023, including clinical development updates and intellectual property strengthening. Consolidated operating loss decreased by 15.7% compared to 2022

Financial Information Clinical Development Intellectual Property Operating Loss AB Science

Published on 05/02/2026 at 00:00, 22 minutes ago

Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 22 minutes ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 1 hour 52 minutes ago

Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 1 hour 52 minutes ago

Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing
Published on 05/01/2026 at 22:30, 1 hour 52 minutes ago

Apex Critical Metals Announces Extension of Marketing Agreement with Rumble Strip Media Inc.

View all ACCESSWIRE

Published on 05/01/2026 at 19:23, 4 hours 58 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 5 hours 41 minutes ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 6 hours 34 minutes ago

Key Figures 30.04.2026
Published on 05/01/2026 at 17:45, 6 hours 36 minutes ago

Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 7 hours ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS

Published on 04/30/2026 at 20:00, 1 day 4 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 5 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 5 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 6 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 1 day 6 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News